| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Otolaryngology-Head and Neck Surgery (G.W., E.M., Z.G., B.T., D.S.), and Division of Endocrinology and Metabolism, Department of Medicine (S.H., P.W.L., M.X.), The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287; and Department of Human Genetics (X.H.), Graduate School of Public Health, Oral Cancer Center (S.M.G.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261
Address all correspondence and requests for reprints to: Dr. Mingzhao Xing, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287. E-mail: mxing1{at}jhmi.edu.
Context: As in many other human cancers, overactivation of the phosphotidylinositol 3-kinase (PI3K)/Akt signaling pathway occurs frequently in thyroid cancer, but the mechanism is not completely clear.
Objective: Because activating mutations and genomic amplification of the PIK3CA gene, which encodes the p110a catalytic subunit of PI3K, are common in many cancers, we sought to investigate this phenomenon in thyroid tumors.
Design: To search for PIK3CA mutations, we isolated genomic DNA from primary thyroid tumors of various types and performed direct sequencing of the exons of PIK3CA gene that carry the most common mutations in other cancers. We used real-time quantitative PCR to investigate genomic amplification of the PIK3CA gene.
Results: We found no PIK3CA gene mutations in 37 benign thyroid adenomas, 52 papillary thyroid cancers, 25 follicular thyroid cancers, 13 anaplastic thyroid cancers, 13 medullary thyroid cancers, and seven thyroid tumor cell lines. We found a C3075T single-nucleotide polymorphism in exon 20 of this gene in two cases. With a copy number of 4 or more defined as amplification, we found PIK3CA gene amplification in four of 34 (12%) benign thyroid adenomas, three of 59 (5%) papillary thyroid cancer, five of 21 (24%) follicular thyroid cancer, none of 14 (0%) medullary thyroid cancer, and five of seven (71%) thyroid tumor cell lines. The PIK3CA gene amplification and consequent Akt activation were confirmed by fluorescence in situ hybridization and Western blotting studies using cell lines, respectively.
Conclusion: These data suggest that mutation of the PIK3CA gene is not common, but its amplification is relatively common and may be a novel mechanism in activating the PI3K/Akt pathway in some thyroid tumors.
This article has been cited by other articles:
 |
|
 |
|
  Y. Cohen, E. Merhavi-Shoham, B. C. R. Avraham-Lubin, M. Savetsky, S. Frenkel, J. Pe'er, and N. Goldenberg-Cohen PI3K/Akt Pathway Mutations in Retinoblastoma Invest. Ophthalmol. Vis. Sci., November 1, 2009; 50(11): 5054 - 5056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cerrato, V. De Falco, and M. Santoro Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets J. Mol. Endocrinol., October 1, 2009; 43(4): 143 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, P. Hou, Z. Liu, G. Wu, and M. Xing Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin Cancer Res., September 15, 2009; 69(18): 7311 - 7319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Psyrri, S. Papageorgiou, E. Liakata, A. Scorilas, D. Rontogianni, C. K. Kontos, P. Argyriou, D. Pectasides, N. Harhalakis, V. Pappa, et al. Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma Clin. Cancer Res., September 15, 2009; 15(18): 5724 - 5732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Krause, B. Jessnitzer, and D. Fuhrer Proteomics in Thyroid Tumor Research J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2717 - 2724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, and Y. Lu Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 301 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Nappi, P. Salerno, H. Zitzelsberger, F. Carlomagno, G. Salvatore, and M. Santoro Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma Cancer Res., March 1, 2009; 69(5): 1916 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liu, P. Hou, M. Ji, H. Guan, K. Studeman, K. Jensen, V. Vasko, A. K. El-Naggar, and M. Xing Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3106 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Abubaker, Z. Jehan, P. Bavi, M. Sultana, S. Al-Harbi, M. Ibrahim, A. Al-Nuaim, M. Ahmed, T. Amin, M. Al-Fehaily, et al. Clinicopathological Analysis of Papillary Thyroid Cancer with PIK3CA Alterations in a Middle Eastern Population J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 611 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Santarpia, A. K. El-Naggar, G. J. Cote, J. N. Myers, and S. I. Sherman Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Riesco-Eizaguirre and P. Santisteban New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xing BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications Endocr. Rev., December 1, 2007; 28(7): 742 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Ball, N. Jin, D. M. Rosen, A. Dackiw, D. Sidransky, M. Xing, and B. D. Nelkin Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4712 - 4718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Joseph, M. Ji, D. Liu, P. Hou, and M. Xing Lack of Mutations in the Thyroid Hormone Receptor (TR) {alpha} and Genes but Frequent Hypermethylation of the TR Gene in Differentiated Thyroid Tumors J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4766 - 4770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Furuya, C. Lu, M. C. Willingham, and S.-y. Cheng Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer Carcinogenesis, December 1, 2007; 28(12): 2451 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Salvatore, T. C. Nappi, P. Salerno, Y. Jiang, C. Garbi, C. Ugolini, P. Miccoli, F. Basolo, M. D. Castellone, A. M. Cirafici, et al. A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma Cancer Res., November 1, 2007; 67(21): 10148 - 10158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, P. Hou, H. Yu, W. Wang, M. Ji, S. Zhao, S. Yan, X. Sun, D. Liu, B. Shi, et al. High Prevalence and Mutual Exclusivity of Genetic Alterations in the Phosphatidylinositol-3-Kinase/Akt Pathway in Thyroid Tumors J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2387 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shinohara, Y. J. Chung, M. Saji, and M. D. Ringel AKT in Thyroid Tumorigenesis and Progression Endocrinology, March 1, 2007; 148(3): 942 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A. K. El-Naggar, G. Tallini, et al. Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1161 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hollestelle, F. Elstrodt, J. H.A. Nagel, W. W. Kallemeijn, and M. Schutte Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines Mol. Cancer Res., February 1, 2007; 5(2): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rudelius, S. Pittaluga, S. Nishizuka, T. H.-T. Pham, F. Fend, E. S. Jaffe, L. Quintanilla-Martinez, and M. Raffeld Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma Blood, September 1, 2006; 108(5): 1668 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G. C. Pansini, M. R. Pelizzo, et al. Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2218 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Parsons Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer Clin. Cancer Res., November 15, 2005; 11(22): 7965 - 7966. [Full Text] [PDF]
|
|
|
|
|
|
D. Liu, E. Mambo, P. W. Ladenson, and M. Xing Letter re: Uncommon Mutation but Common Amplifications of the PIK3CA Gene in Thyroid Tumors J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5509 - 5509. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
